SPECT studies of D2 occupancy in low-dose haloperidol treatment.
Hirschowitz
J
J
Hitzemann
R
R
Vallabhajosula
S
S
D000328:Adult; D001479:Basal Ganglia / Q000378:metabolism; D001549:Benzamides; D002531:Cerebellum / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D012565:Schizophrenic Psychology; D015899:Tomography, Emission-Computed, Single-Photon
D001549:Benzamides; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D006220:Haloperidol